問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of Others-Lung Cancer

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

National Taiwan University Cancer Center (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

施金元SHIH, JIN-YUAN
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

241Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

施金元

List

398Cases

2016-02-22 - 2022-12-22

Phase II

A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    INC280

Participate Sites
6Sites

Recruiting5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-06-08 - 2019-09-16

Phase II

A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-Positive Non Small Cell Lung Cancer metastatic to the brain and/or to leptomeninges

  • Condition/Disease

    ALK-Positive Non Small Cell Lung Cancer metastatic to the brain and/or to leptomeninges

  • Test Drug

    LDK378

Participate Sites
3Sites

Terminated3Sites

2012-10-22 - 2014-11-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-07-01 - 2012-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2019-02-22 - 2022-01-31

Phase III

A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    Ilaris

Participate Sites
3Sites

Terminated3Sites

2022-09-01 - 2024-07-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting2Sites

Terminated4Sites

2016-01-31 - 2017-02-10

Phase I

A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1)) will evaluate the safety, tolerability, PK, IM, and antitumor activity of MEDI4736 in adult patients with solid tumors. A dose exploration cohort will look at the safety profile of Q4W dosing of MEDI4736.

  • Condition/Disease

    NSCLC

  • Test Drug

    MEDI4736 & Tremelimumab

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

2024-04-01 - 2027-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-06-01 - 2030-05-31

Phase II/III

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    Fianlimab (REGN3767)Cemiplimab (REGN2810)

Participate Sites
9Sites

Recruiting9Sites

2020-03-10 - 2026-05-21

Phase I

A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    CLN-081

Participate Sites
7Sites

Recruiting7Sites

1 36 37 38 39 40
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB